Know Who Will Respond-Before You Spend.
A one-time genetic test that predicts GLP-1 response before coverage approval—helping payers reduce wasted spend, improve utilization, and drive measurable outcomes.
1 in 5 patients are genetically unlikely to respond to GLP-1 therapy.
The Problem
Up to 20 % of patients carry variants that make GLP-1 therapy ineffective—driving wasted spend and early discontinuation.
How it Works
Polygenic Risk Score
GLP1R (4 variants)
Your GLP-1 receptor genes influence how your body responds to medications like semaglutide and how effectively you manage appetite and blood sugar.
CNR1 (rs1049353)
This gene affects how your brain and body regulate appetite and cravings through the endocannabinoid system.
CTRB1
Your CTRB1 gene impacts pancreatic enzyme function and can affect how well GLP-1–based treatments work for you.
Stratifies likelihood of response and tolerability risk; results pre-Rx, API-ready for PA workflows.
Future Roadmap: ARRB1
The BlueGenes Advantage
Test Before You Spend:
One-time test vs. recurring $12K–$15K therapy.
Predict Who Will Respond Before Approval:
Genetic stratification identifies patients 2× more likely to achieve clinically meaningful weight loss and sustained adherence.
PGx-Informed Coverage Decisions:
Objective genetic criteria reduce appeals, support defensible prior auth logic, and improve utilization management.
Frequently Asked Questions
Roughly 20 % of the population carry variants linked to reduced GLP-1 efficacy or poor tolerability.
Yes. GLP1R evidence is strong across four variants tested by BlueGenes, consistent with known mechanism of action. CNR1 and CTRB1 are emerging signals with biologic plausibility. Population-level benefit is supported; validation continues.
Tested Variants (GLP-1 Response Panel):
- GLP1R (rs6923761, rs10305420, rs2268641, rs3765467)
- CNR1 (rs1049353)
- CTRB1 (rs7202877)
Future roadmap: ARRB1 (not included in current test).
No absolutes. This test stratifies odds of response and tolerability risk at the population level, improving payer and provider decision-making.
This is a CLIA-certified, lab-developed test. It supports clinical decision-making and payer workflows but is not a therapeutic label claim.
Provider submits PA → test ordered → result returns alongside → informs coverage determination. API integration minimizes disruption.
One-time test offsets thousands in wasted therapy spend and appeals. Example: $12–15K annual therapy exposure vs. <$500 test.